文献速递胸部肿瘤放疗

化疗可改善接受根治性放疗的T2N0M0非小细胞肺癌患者总生存:基于SEER数据库的分析

Addition of chemotherapy improves overall survival in patients with T2N0M0 non-small cell lung cancer undergoing definitive radiation therapy: An analysis of the SEER database.
PubMed 文献 · Radiother Oncol · 2018-12-31

该研究利用SEER数据库筛选2004至2015年接受放疗而未手术的T2N0M0非小细胞肺癌患者,按AJCC第6版和第7版分别分析化疗与总生存的关系。结果显示化疗组在AJCC第6版T2和AJCC第7版T2b(5-7 cm)患者中五年总生存显著更长,但在T2a(3-5 cm)中无显著差异。作者认为化疗可能使肿瘤大于5 cm的非腺癌患者获益。

要点

  • AJCC第6版T2患者化疗组五年总生存19.9% vs 非化疗组15.8%,p=0.0023。
  • AJCC第7版T2b(5-7 cm)化疗组五年总生存20.9% vs 非化疗组13.6%,p=0.0046。
  • AJCC第7版T2a(3-5 cm)化疗组与非化疗组五年总生存无显著差异(24.3% vs 21.1%,p=0.4369)。

核心结论

  • 该研究强烈提示化疗可能使肿瘤大于5 cm(AJCC第8版T3)的非腺癌患者在接受胸部放疗时获益。

研究设计与样本

  • 利用SEER数据库筛选2004至2015年接受放疗而未手术的T2N0M0非小细胞肺癌患者。
  • T分期依据AJCC第6版(2004年起)和第7版(2010年起)定义。
  • 按化疗状态采用单因素和多因素分析评估总生存。
  • AJCC第6版(T2;3-7 cm)共纳入6075例患者。
  • AJCC第7版(T2a;3-5 cm,T2b;5-7 cm)共纳入3138例患者。

主要发现

  • 化疗与较年轻年龄、男性、非腺癌和高病理分级相关。
  • AJCC第6版T2患者化疗组五年总生存19.9% vs 非化疗组15.8%,p=0.0023。
  • AJCC第7版T2b(5-7 cm)患者化疗组五年总生存20.9% vs 非化疗组13.6%,p=0.0046。
  • AJCC第7版T2a(3-5 cm)患者化疗组与非化疗组五年总生存无显著差异(24.3% vs 21.1%,p=0.4369)。
  • 多因素分析显示化疗是AJCC第6版T2和AJCC第7版T2b的独立预后因素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Despite recommendations by clinical guidelines, an advantage of adding systemic chemotherapy to definitive radiation in patients with early stage non-small cell lung cancer (NSCLC) has never been demonstrated by randomized or large-scale studies. This study evaluates the role of chemotherapy in T2N0M0 NSCLC patients who did not undergo surgical resection. MATERIALS AND METHODS: Using the Surveillance, Epidemiology, and End Results (SEER) database, we screened for patients with T2N0M0 NSCLC who received radiation therapy without surgical resection from 2004 to 2015. T-staging was defined according to the American Joint Committee on Cancer (AJCC) 6th (Year 2004+) and 7th (Year 2010+) versions. Overall survival based on chemotherapy status was assessed by univariate and multivariate analyses. RESULTS: A total of 6075 and 3138 patients were identified for AJCC 6th (T2; 3-7cm) and 7th (T2a; 3-5 cm, T2b; 5-7 cm) version, respectively. Administration of chemotherapy was associated with younger age, male sex, non-adenocarcinoma, and high pathologic grade. Kaplan-Meier's estimates demonstrated that the chemotherapy group had a statistically significant longer five-year overall survival than the non-chemotherapy group in patients with AJCC 6th T2 (19.9% vs 15.8%, p = 0.0023) and AJCC 7th T2b (5-7 cm, 20.9% vs 13.6%, p = 0.0046) but not those with AJCC 7th T2a (3-5 cm, 24.3% vs 21.1%, p = 0.4369). Multivariate analyses also revealed that the use of chemotherapy was an independent prognostic factor in AJCC 6th T2 and AJCC 7th T2b. CONCLUSIONS: This study strongly suggests that chemotherapy may benefit non-adenocarcinoma patients with primary tumor larger than 5 cm (AJCC 8th T3) undergoing chest radiation.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Komiya T, Chaaya G, Powell E, et al. Addition of chemotherapy improves overall survival in patients with T2N0M0 non-small cell lung cancer undergoing definitive radiation therapy: An analysis of the SEER database. Radiother Oncol. 2018. PMID: 30773190. doi:10.1016/j.radonc.2018.12.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。